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Abstract
Purpose To review the current literature on the psychological
impact of anti-VEGF treatments for wet age-related macular
degeneration (wAMD), in terms of patients’ experiences of
receiving these treatments, and the impact of these treatments
for patients’ mental health and quality of life.
Methods We critically analyzed current literature evaluating
psychological impact of anti-VEGF treatments for wAMD.
Primary searches of PubMed, Science Direct, and Web of
Science were conducted in July and August of 2015. We
reviewed all papers on the topic published until August 5,
2015.
Results Our literature search found 14 papers addressing the
psychological impact of anti-VEGF treatments for wAMD.
Results highlighted potential anxieties and experiences of pain
caused by receiving regular intravitreal injections. A positive
visual outcome of anti-VEGF therapy is associated with posi-
tive vision-related QOL outcomes, although such association
seems to be dependent on improvements on visual acuity. In the
literature reviewed, patients receiving anti-VEGF treatments
showed a prevalence rate of depression between 20 and 26 %.
Conclusions Although anti-VEGF treatments can cause some
anxiety and being experienced as a stressful event, especially
in the beginning of the treatment, preliminary findings suggest
a potential benefit for long-term vision-related quality of life.
Further longitudinal and qualitative research should bring
more evidence on the positive and negative effects of these
treatments on patients’ long-term mental health.
Keywords Wet age-related macular degeneration .
Anti-VEGF treatment . Psychological impact . Intra-vitreal
injections
Introduction
Age-related macular degeneration (AMD) is currently the
leading cause of irreversible vision loss and blindness in peo-
ple aged 50 and older, particularly in the developed world [1].
AMD can be a highly disabling condition, causing impairment
to the activities of daily living, invoking emotional distress,
anxiety, and depression [2]. Currently, wet macular degenera-
tion (wAMD) is the only form of AMD that is treatable, usu-
ally involving the use of vascular endothelial growth factor
inhibitors (anti-VEGF) such as ranibizumab, aflibercept, or
bevacizumab [3]. These treatments are regarded as having
great potential for halting disease progression and for reducing
further risk of blindness [3].
However, these treatments are administrated by invasive
intra-vitreal injections, often at the conclusion of lengthy, fre-
quent, and oft-repeated visits after transport to an eye clinic.
The specific act of an intraocular anti-VEGF injection can be
experienced by patients as a stressful event, especially in the
beginning of treatment [4, 5]. Furthermore, anti-VEGF treat-
ments are frequently without a pre-established date for their
completion, and this concept can entail additional anxiety to
some patients.
In order to optimize patients’ quality of life, it would seem
prudent to not only target the impact of treatments on vision
but also the impact of the repeated injection visits themselves
on patients’ well-being and mental health. It is therefore
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crucial to understand how patients experience these invasive
treatments and how they manage any related anxieties.
Additionally, it is relevant to investigate the separate issue of
whether the protective effect that these treatments have on
vision is also followed by any benefits on patients’ mental
health and quality of life, or if the treatment benefits are ex-
clusive to patients’ vision. Both questions are of importance
for everyday clinical management of these patients, but unfor-
tunately both are still poorly answered due to paucity of rele-
vant research.
Methods
With this review, we want to critically analyze the current
literature on the psychological impact of anti-VEGF treat-
ments for wAMD. We selected all studies that fulfilled the
following inclusion criteria: articles published in English;
peer-reviewed articles; studies of adults with wAMD;
studies addressing anti-VEGF treatments for wAMD;
studies focused on the psychological and psychosocial
implications of receiving anti-VEGF treatments for
wAMD including the experience of receiving treatment,
quality of life, anxiety, stress, and depression. We only
considered studies investigating psychological conse-
quences of receiving anti-VEGF injections for wAMD.
Studies addressing the psychological impact of wAMD
without controlling for intravitreal injections or studies
conducted with patients who did not receive these treat-
ments were excluded. We also excluded studies exclusive-
ly focused on pain levels induced by anti-VEGF injec-
tions or on factors associated with pain caused by injec-
tions because we do not consider pain as a psychological
variable and therefore it cannot be regarded as part of the
psychological impact of anti-VEGF treatment. Systematic
reviews were considered in this review as they summarize
pre-existent literature and evidence on the topic.
Two authors (H.S. and Z.C.A.) systematically conducted a
search of electronic databases (PubMed, Web of Science, and
Science Direct) to retrieve all articles published up to August
5, 2015. We searched these databases using terms that are
often used in literature to designate AMD, anti-VEGF treat-
ments and its psychological impact, including Bmacular
degeneration^ and Banti-VEGF^; Bmacular degeneration^
and Bpsychological^; Bmacular degeneration^ and
Bdepression^; Bmacular degeneration^ and anxiety^; Banti-
V EGF ^ a n d Be x p e r i e n c e ^; Ba n t i - V EGF ^ a n d
Bpsychological^; Banti-VEGF and Bdepression^; Banti-
VEGF^ and Banxiety^; Banti-VEGF^ and Bquality of life^;
Bintravitreal^ and Banxiety^; Bintravitreal^ and Bdepression^;
Bintravitreal^ and Bpsychological^; Bintravitreal^ and Bquality
of life^. Additional sources were identified through cited and
citing articles.
Two authors (H.S. and Z.C.A.) independently reviewed
titles and abstracts and then the full-text articles to identify
the eligible studies. Results of both researchers were com-
pared, and clearly non-eligible studies were excluded. Then,
duplicates were removed from the list. Next, the same re-
searchers read the abstracts of the remaining articles to deter-
mine whether they met inclusion criteria. Abstracts providing
sufficient detail for exclusion were removed, and the remain-
ing full-text articles were retrieved. Full-text articles were read
to determine inclusion, and disagreements were resolved via
consensus and returning to the articles. Data were analyzed
and summarized using a specific table (Table 1).
Results
Figure 1 describes the process of study selection. We identi-
fied 282 articles from the databases, of which 195 were ex-
cluded on the basis of title review, leaving 87 articles. Of 87
articles, we excluded 35 for being duplicates and 40 for not
meeting our eligibility criteria, with 12 articles remaining for
review. Reference lists were reviewed using the same process,
and two additional articles were identified for inclusion, leav-
ing a final list of 14 articles to be reviewed [4–17]. The main
reasons for not meeting the eligibility criteria of this review
were samples not exclusively composed of patients with
wAMD, studies about the psychological impact of anti-
VEGF in other medical conditions, or studies exclusively fo-
cused on other consequences of wAMD such as pain or on the
effect of anesthetics on pain levels experienced by patients.
Table 1 summarizes all articles included in the current re-
view. The year of publication ranges from 2009 to 2015. Six
articles reported observational non-interventional studies
[10–14, 17] and three articles reported qualitative studies [5,
7, 9]. The remaining articles reviewed were one systematic
review [4], one prospective clinical survey [6], one prospec-
tive cases series case series study [8], one cross-sectional
study [15], and one longitudinal study [16]. With regards to
the type of anti-VEGF treatment received by patients,
ranibizumab was used in eight studies [6, 8–13, 15], while
bevacizumab was only used in two studies [7, 17]. One study
used ranibizumab and bevacizumab [16] and two other studies
did not state which type of anti-VEGF had been administrated
to patients [5, 14]. The systematic review reported studies in
which ranibizumab and bevacizumab were used [4]. Studies
included in this review investigated the psychological impact
of anti-VEGF treatments by exploring one of the following
topics: (1) Patients’ experiences or perspectives of the process
of receiving anti-VEGF treatments for wAMD [4–9]; (2)
Longer-term impact of anti-VEGF treatments on patients’
quality of life [10–13]; and (3) Depression/anxiety after re-
ceiving anti-VEGF treatments for wAMD [14–17].
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Patients’ experiences of the process of receiving
anti-VEGF treatments for wAMD
Our review found six articles on patients’ experiences or perspec-
tives of receiving anti-VEGF treatments for wAMD [4–9].
Findings generally highlighted frequent experiences of discom-
fort and fear associated with receiving anti-VEGF treatment over
time [4, 5, 7–9]. The aspects of the treatment in which patients
reported more discomfort were: needle entry; application of
drops; insertion of speculum; waiting for injection; experiences
of pain, fear of losing sight, fear for the unknown, and side
effects. The most recent study we found on patient experiences
of anti-VEGF highlighted the complexity and diversity of pa-
tients’ experiences of treatment. This study suggested, for the
first time, patients’ Bcautious optimism^ as a valid response to
treatment success. However, one study found that discomfort and
fearful experiences were mainly circumscribed to the first injec-
tion and strongly related to the patients’ previous expectations of
treatment [6]. Finally, the systematic review on the experiences
of anti-VEGF treatments [4] included four studies that were also
analyzed by us [6–9] and six other studies focused on pain levels
caused by anti-VEGF treatment and the effect of anesthetics on
pain experienced by patients [8, 18–22]. Findings highlighted the
fact that patients’ expectations of pain before they started the
treatment were higher than the pain experienced when receiving
the treatment. Finally, the review suggested the need for more
research, particularly to clarify the reasons underlying patients’
anxieties when receiving anti-VEGF treatments, and more qual-
itative studies addressing patients’ experiences of receiving the
treatments.
Longer-term impact of anti-VEGF treatments on patients’
quality of life
Studies reviewed found an improvement on patients’ vision-
related quality of life after they have started receiving
282 articles identified in database search
117 articles form PubMed 
72 articles from Web of Science 
93 articles from Science Direct 
195 reports excluded based on 
title review 
87 potential eligible 
reports included 
35 duplicates excluded
52 reports retrieved 
for abstract review 
24 reports excluded: didn’t 
fulfil with our eligibility 
criteria 
28 reports retrieved 
for full-text review 
16 reports excluded for didn’t 
fulfil with our eligibility 
criteria 
2 additional studies 
identified from 
reference lists 
12 studies identified to 
be reviewed 
14 studies selected 
for review 
Fig. 1 Flow diagram of articles
selection for review
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intravitreal treatment with ranibizumab for wAMD [10–13].
This relationship was found to be very dependent on improve-
ments in patients’ visual acuity [10–13]. One study found an
improvement on patients’VRQL at month 3 of treatment [10]
and another study found improvements at month 4 of treat-
ment [11]. Two other studies found better vision-related qual-
ity of life after 12months of treatment [11, 13]. Of four articles
identified, three used the National Eye Institute Visual
Function Questionnaire (NEI VFQ-25) [23] to assess patients’
vision-related quality of life. This instrument comprises the
assessment of general health, quality of vision, and vision-
related quality of life that includes dependency, role limita-
tions, mental health, social functioning, ocular pain, and driv-
ing. In general these studies found an improvement on pa-
tients’ vision-related quality of life after they have started re-
ceiving intravitreal treatment with ranibizumab for wAMD.
An improvement on patients’ mental health was also associ-
ated with receiving these treatments [10–13].
Depression and anxiety after anti-VEGF treatments
for wAMD
A preliminary study has explored depression in wAMD pa-
tients receiving anti-VEGF treatments [14]. In this study, de-
pression was assessed using the NEI VFQ [23]. Results sug-
gested a slightly lower prevalence rate of depression among
patients receiving anti-VEGF treatments in comparison with
previous studies in which depression rates were not adjusted
for anti-VEGF treatments. Additionally, patients with depres-
sion were found to have a greater decline in vision. Finally,
depression was unrelated to changes in NEI-VFQ or obstacles
to treatment.
With different results, a study conducted with 107 Korean
patients with wAMD receiving intravitreal ranibizumab treat-
ment found a prevalence of depression of 26.2 %, which is
consistent with the literature pre-anti-VEGF treatments [15].
In this study, depression was assessed using the Geriatric
Depression Scale [24].
A retrospective study analyzed the incidence of a primary
diagnosis of depression among Medicare beneficiaries in the
US diagnosed with wAMD during a 2-year follow-up period
[16]. In this study, the diagnosis of depression was identified
from the enrolment information and Medicare claims filed on
behalf of beneficiaries. This study reported no significant dif-
ferences in the incidence of depression between patients re-
ceiving anti-VEGF treatments and those who did not.
Furthermore, a first diagnosis of depression during the
follow-up period only occurred in 2.0 % of the whole sample.
Finally, a recent prospective observational study conducted
in Israel found a significant correlation between patients’ anx-
iety levels experienced before the injection and pain experi-
enced when receiving the injection [17]. In this study, 25 % of
the participants reported high levels of anxiety measured by a
visual analogue scale (score≥6 on a scale from 0 to 10).
Discussion
Our review shows that the psychological impact of anti-VEGF
treatments for wAMD remains a relatively new topic with
limited evidence and therefore requires more research. To
date, the psychological impact of receiving anti-VEGF treat-
ments for wAMD has been addressed in studies focused on
the patient experience of receiving these treatments, the im-
pact of anti-VEGF treatments for patients’ vision-related qual-
ity of life, and mental health.
The patient experience of receiving anti-VEGF has been
the most addressed topic in previous studies about the psycho-
logical impact of these treatments for wAMD. In this topic, we
found five articles [5–9] and one systematic review in which
ten articles were reviewed [4]. Findings suggested that, in
general, this treatment is well tolerated by patients, but a great
portion of them were still anxious about the treatment.
According to these studies, patients feel anxious especially
because of previous expectations of receiving a needle in the
eye, fear of losing their sight, fear of any side effects, and prior
experiences of pain when receiving intravitreal injections.
Furthermore, as a recent study highlighted [5], anti-VEGF
treatments can have significantly changed the way patients
experience this disease and cope with the fear for blindness,
because now patients come across with a treatment with great
potential for halting disease progression. Studies conducted
prior to availability of anti-VEGF treatments considered a
patients’ optimism about the medical treatments and disease
progression as false hope and a non-adapted behavior [25], but
patients’ cautious optimism about the disease progression can
now be acceptable in the light of positive outcomes offered by
anti-VEGF treatments and the way the wAMD prognosis is
now communicated to patients [5]. However, there are some
aspects of the experience of receiving anti-VEGF treatments
needing more attention. In this review, we only found three
studies exploring in-depth patients’ experiences of receiving
anti-VEGF treatments using a qualitative design [5, 7, 9]. The
remaining studies that have addressed the experience of re-
ceiving anti-VEGF treatment were mainly focused on pain
caused by the treatment. It is of paramount importance to
generate more evidence on how patients experience these
treatments, especially through qualitative research, which
could yield high-quality information and is a field as yet large-
ly unexplored [4]. Such evidence is crucial to understand pa-
tients’ main sources of anxiety and what strategies patients
activate to effectively cope with these treatments.
The literature we reviewed suggested that anti-VEGF treat-
ments can have a positive impact on patients’ vision-related qual-
ity of life, albeit such a relationship is dependent on
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improvements in VA [10–13]. In these studies, the concept of
vision-related quality of life included not only a patient’s aspects
related to the use of vision in activities of everyday life but also
mental health and social functioning. These findings therefore
suggested a strong link between VA and patients’ perceptions
of quality of life, functioning, and mental health. However, fur-
ther research should clarify this link as, according to a recent
systematic review, not all previous studies found a strong rela-
tionship between VA and adjustment to vision loss or depression
after vision loss [26].
There is strong evidence that AMD patients are likely to be
depressed and anxious as a consequence of limitations imposed
by vision loss [1, 2, 27, 28]. Both conditions are regarded as the
most frequent mental health problems among people with AMD
with rates ranging from 15.7 to 44 % for depressive symptoms
and 9.6 to 30.1 % for anxiety symptoms [2]. Depression would
be an additional source of disability for these patients and can
compromise the response to the treatment and medical outcomes
[1, 2, 29]. Previous studies found high comorbidity of depression
andAMDbutmost of them did not control for patients whowere
receiving anti-VEGF treatments [20, 29]. It is important to con-
sider the potential influence of anti-VEGF treatments on preva-
lence of depression because some studies have suggested a pos-
itive correlation between visual acuity and adjustment to vision
loss [26–28], mental health [10–13], and quality of life [10–13].
In our review, we found three studies addressing depression after
receiving anti-VEGF treatments for wAMD [14–17]. Two of
them suggest no influence of anti-VEGF treatments on preva-
lence rates of depression. However, in one of these studies [15],
findings should be carefully analyzed because: (a) the authors did
not provide any details on how depression was measured and
diagnosed during the follow-up period; and (b) the incidence
rates of depression found in this study are oddly lower than those
found in previous studies in which standardized and valid instru-
ments were used to measured depression [2]. Finally, the only
study that assessed the levels of anxiety associatedwith receiving
anti-VEGF injections suggested that anti-VEGF treatment can
induce clinical anxiety, and that the levels of anxiety found are
within the range of prevalence of anxiety described in previous
studies evaluating psychological impact of AMD [2].
Some limitations should be acknowledged in this review.
First, only articles in English were included in this review,
which can be considered a limitation because there are studies
on the topic published in other languages. Second, the termi-
nology used to perform the search for articles reflects not only
the state of the art but also our previous experience and per-
haps bias in the field. Finally, this review did not include grey
literature such as academic dissertations or conference ab-
stracts, and therefore there could be other studies addressing
this topic that were not reviewed.
In conclusion, there is still very little knowledge on the psy-
chological impact of anti-VEGF treatments for wAMD. Future
studies, especially longitudinal research, should bring more
evidence on this topic and clarify the positive and /or negative
impact that this treatment can have for patients’ mental health
and quality of life. An awareness of the likely psychological
impact on individual patients should allow physicians to decide
holistically, which are themost appropriate treatment strategies to
adopt. Such knowledge will be key to developing evidence-
based clinical strategies to help patients to manage the treatment
and reduce anxiety and pain levels along the treatment. An ex-
ploration of depression in patients receiving anti-VEGF treat-
ments would also be valuable for developing new intervention
strategies to prevent long-term mental health problems among
these patients. Additionally, it will be helpful to prevent any
patient drop-outs, which can compromise any positive outcomes
brought by anti-VEGF treatments. Because ant-VEGF treat-
ments are being used with other ophthalmologic conditions rath-
er than wAMD, it would be relevant to study experiences of
treatment, adherence to treatment, mental health, and quality of
life across other conditions such as diabetic macular edema or
choroidal neovascularization secondary to pathologic myopia.
The specific case of macular edema deserves special attention
because there is evidence of a strong link between diabetes and
depression, regardless the co-existence of vision loss [30–32].
Great advances have been made over the last decade in
treating a generation of patients for whom there had previously
been no hope for visual gain and further research on psycholog-
ical impact of anti-VEGF treatments should expand on such
advances for the overall welfare and benefit of patients with
retinal disease.
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